Department of Pathology and Laboratory Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania 19134, USA.
Histol Histopathol. 2012 Sep;27(9):1183-94. doi: 10.14670/HH-27.1183.
We and others have previously shown that increased expression and altered compartmentalization of γ-tubulin may contribute to tumorigenesis and tumor progression (J. Cell Physiol. 2009;223:519-529; Cancer Biol. Ther. 2010;9:66-76). Here we have determined by immunohistochemistry the localization and cellular distribution of γ-tubulin in clinical tissue samples from 109 non-small cell lung cancer (NSCLC) cases. The expression and distribution of γ-tubulin protein and transcripts was also determined in the NSCLC tumor cell lines NCI-H460 (HTB-177) and NCI-H69 (HTB-119) by immunocytochemistry, quantitative immunoblotting and reverse transcription quantitative real-time PCR (RT-qPCR). Polyclonal and monoclonal anti-peptide antibodies recognizing epitopes in the C- or N-terminal domains of γ-tubulins and human gene-specific primers for γ-tubulins 1 (TUBG1) and 2 (TUBG2) were used. In non-neoplastic cells of the airway epithelium in situ, γ-tubulin exhibited predominantly apical surface and pericentriolar localizations. In contrast, markedly increased, albeit heterogeneous and variously prominent γ-tubulin immunoreactivity was detected in clinical tumor specimens and in the NCI-H460 and NCI-H69 cell lines, where tumor cells exhibited overlapping multi-punctate and diffuse patterns of localization. Co-expression of γ-tubulin and Ki-67 (MIB-1) was detected in a population of proliferating tumor cells. A statistically significant increase of γ-tubulin expression was found in Stage III compared to lesser stage tumors (p<0.001 v. Stages I/II) regardless of histological subtype or grade. By quantitative immunoblotting NCI-H460 and NCI-H69 cells expressed higher levels of γ-tubulin protein compared to small airway epithelial cells (SAEC). In both tumor cell lines increase in TUBG1 and TUBG2 transcripts was detected by RT-qPCR. Our results reveal for the first time an increased expression of γ-tubulin in lung cancer.
我们和其他人之前已经表明,γ-微管蛋白的表达增加和区室化改变可能有助于肿瘤发生和肿瘤进展(J. Cell Physiol. 2009;223:519-529; Cancer Biol. Ther. 2010;9:66-76)。在这里,我们通过免疫组织化学方法确定了 109 例非小细胞肺癌(NSCLC)临床组织样本中γ-微管蛋白的定位和细胞分布。通过免疫细胞化学、定量免疫印迹和逆转录定量实时 PCR(RT-qPCR),还确定了 NSCLC 肿瘤细胞系 NCI-H460(HTB-177)和 NCI-H69(HTB-119)中γ-微管蛋白蛋白和转录本的表达和分布。使用识别 γ-微管蛋白 C 或 N 末端结构域表位的多克隆和单克隆肽抗体以及针对 γ-微管蛋白 1(TUBG1)和 2(TUBG2)的人基因特异性引物。在原位气道上皮的非肿瘤细胞中,γ-微管蛋白主要表现为顶表面和中心体周围定位。相比之下,在临床肿瘤标本和 NCI-H460 和 NCI-H69 细胞系中检测到明显增加的、尽管异质且表现各异的 γ-微管蛋白免疫反应性,其中肿瘤细胞表现出重叠的多点状和弥漫性定位模式。在增殖性肿瘤细胞的一部分中检测到 γ-微管蛋白和 Ki-67(MIB-1)的共表达。与较小阶段的肿瘤相比(p<0.001 v. Stages I/II),无论组织学亚型或分级如何,在 III 期发现 γ-微管蛋白表达的统计学显著增加。通过定量免疫印迹,NCI-H460 和 NCI-H69 细胞表达的 γ-微管蛋白蛋白水平高于小气道上皮细胞(SAEC)。在这两个肿瘤细胞系中,通过 RT-qPCR 检测到 TUBG1 和 TUBG2 转录本的增加。我们的研究结果首次揭示了肺癌中 γ-微管蛋白表达的增加。